Advanced Filters
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
noise

Found 2,823 clinical trials

J Jürgen Debus, Prof.

Tissue Retractors for Radiation Therapy of Head and Neck Tumors

The rate of therapy-associated side effects during and after radiotherapy of head and neck tumors is essential. The most effective approach to reducing acute toxicity is to cut out healthy tissue from the radiation field. The distance between the tumor and normal tissue can be individually increased using personalized, 3D …

18-99 years All Phase 2
B BeiGene

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

The primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant treatment versus participants receiving placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed …

18 years and older All Phase 3
W W John Martin, MD, PhD

Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals

Preliminary reports have been received from several sources that the periodic inhaling of water with a heightened level of kinetic activity has lessened the severity of symptoms in Covid-19 infected patients. On at least several occasions, a repeat PCR test performed two days after inhaling a particular water-based product was …

100 years and younger All Phase N/A
A Ayotola Onipede, B.S.

Peer-Led Dissonance Eating Disorder Prevention: Virtual Delivery

This proposed pilot study will evaluate whether this body acceptance class produces greater reductions in eating disorder risk factor symptoms (pursuit of the thin ideal, body dissatisfaction, dieting, dietary restraint and negative affect), eating disorder symptoms, and future onset of eating disorders over 6-month follow-up in this population.

16-26 years Female Phase N/A
F Francesca Gany, MD, MPH

Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer

This study will compare the effectiveness of the Masterful supportive care intervention with that of the non-faith-based active control supportive care intervention, which uses the American Cancer Society's patient education materials, for Muslim patients who have advanced cancers.

18 years and older All Phase N/A
I Ingeborg Vriens

Comparative Study 27G Vitrectomy vs Larger Gauge Surgery

Two-arm, mono-center, prospective, interventional comparative case study to compare postoperative recovery between the 27G and larger gauge surgical approach.

18 years and older All Phase N/A
H Holly Blake, PhD

Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study

Evaluation of a workplace intervention to implement supported wellbeing centres in a healthcare workplace during and after the COVID-19 pandemic. Mixed-Methods Evaluation study - including collection of service use monitoring data, online survey and qualitative interviews.

100 years and younger All Phase N/A
J Joan Gilmore

Cyclosporine in Patients With Moderate COVID-19

Phase 1 safety study to determine the tolerability, clinical effects, and changes in laboratory parameters of short course oral or IV cyclosporine (CSA) administration in patients with COVID-19 disease requiring oxygen supplementation but not requiring ventilator support.

18 years and older All Phase 1
U US GSK Clinical Trials Call Center

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. This study will be used to define the recommended Phase 2 dose (RP2D). The …

18 years and older All Phase 1
T Tycel Phillips, MD

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, …

18 years and older All Phase 1

Simplify language using AI